Terminal transferase enzyme assay and immunological membrane markers in the diagnosis of leukaemia: a multiparameter analysis of 300 cases

British Journal of Haematology
G JanossyT A Lister

Abstract

Multiparameter analyses have been carried out with recently developed enzyme and membrane markers in 300 patients with various leukaemias including ALL, AML, but excluding Ph1 positive leukaemias. TdT enzyme levels were particularly valuable in the differential diagnosis of adult acute lymphoid and myeloid leukaemias. The levels were raised in 108 (94%) of the 115 patients who were considered to be non-T, non-B ALL on membrane marker and morphological analysis; all seven cases giving negative TdT results in this group were young children. Unexpectedly high levels were seen only in three (4.1%) of 73 cases of acute myeloid leukaemia verified by histochemistry and membrane markers. Anti-ALL serum was a most useful reagent in childhood leukaemias but blasts from 19 patients (10% of childhood ALL cases and 29% of adult ALL cases) failed to react with the serum in spite of TdT positivity. Strongly ALL+ blasts were seen only in non-T, non-B ALL and some undifferentiated leukaemias. Weakly ALL+ blasts were seen in seven of 32 cases of thymic ALL (Thy-ALL) but in other respects these blasts expressed Thy-ALL features, such as strong reactivity with anti-T cell (HuTLA) serum, negativity with anti-Ia-like serum and raised TdT. The combin...Continue Reading

References

Sep 1, 1977·Proceedings of the National Academy of Sciences of the United States of America·R J WinchesterH E Broxmeyer
Sep 1, 1977·European Journal of Immunology·I S TrowbridgeG Klein
Nov 1, 1977·British Journal of Haematology·G JanossyK Welsh
Dec 1, 1976·The Journal of Clinical Investigation·S BroderT A Waldmann
May 1, 1977·The Journal of Clinical Investigation·M F GreenwoodP Holland
Oct 1, 1977·Scandinavian Journal of Haematology·G JanossyD S Thompson
Mar 2, 1978·The New England Journal of Medicine·R B EllisM F Greaves
Jan 1, 1977·Haematology and Blood Transfusion·H RodtS Thierfelder
Apr 20, 1978·The New England Journal of Medicine·L B VoglerM D Cooper
Sep 1, 1977·Proceedings of the National Academy of Sciences of the United States of America·K E GregoireF J Bollum
Apr 1, 1978·British Journal of Haematology·M M Roberts, M F Greaves
Oct 27, 1978·Biochimica Et Biophysica Acta·M Greaves, G Janossy
Oct 1, 1975·Proceedings of the National Academy of Sciences of the United States of America·F J Bollum
Apr 10, 1975·The New England Journal of Medicine·R McCaffreyD Baltimore
Apr 1, 1976·Proceedings of the National Academy of Sciences of the United States of America·S F SchlossmanJ L Strominger
Aug 1, 1976·The Journal of Experimental Medicine·A E SilverstoneD Baltimore
May 1, 1975·Clinical Immunology and Immunopathology·M F GreavesT A Lister
Nov 23, 1974·Lancet·S E Salmon, M Seligmann
Aug 1, 1971·The Australian Journal of Experimental Biology and Medical Science·D Metcalf

❮ Previous
Next ❯

Citations

Nov 1, 1981·European Journal of Pediatrics·A H Wojciechowski, J Pritchard
Apr 1, 1983·Journal of Clinical Immunology·I G Barr, B H Toh
Oct 30, 1987·Clinica Chimica Acta; International Journal of Clinical Chemistry·D M Goldberg, D Brown
Jan 1, 1981·Leukemia Research·M F GreavesG Goldstein
Jan 1, 1983·Leukemia Research·P JaniF Bollum
Mar 1, 1981·Journal of Clinical Pathology·A V Hoffbrand, G Janossy
Feb 1, 1985·Journal of Clinical Pathology·H G DrexlerJ Minowada
Jun 19, 2009·Epidemiologic Perspectives & Innovations : EP+I·Andrew C Ward
Mar 3, 2004·Cytometry. Part a : the Journal of the International Society for Analytical Cytology·Alberto OrfaoJesus San Miguel
Mar 21, 2007·American Journal of Clinical Pathology·Xin Han, Carlos E Bueso-Ramos
Jan 1, 1983·Leukemia Research·M F GreavesT A Lister
Jan 1, 1987·Leukemia Research·U R KeesR P Herrmann
Aug 1, 1989·British Journal of Haematology·K F BradstockW G Hughes
Dec 1, 1981·British Journal of Haematology·K F BradstockA V Hoffbrand
Aug 1, 1982·British Journal of Haematology·G TricotR L Verwilghen
Nov 1, 1981·British Journal of Haematology·F BreatnachM F Greaves
Oct 1, 1990·Baillière's Clinical Haematology·D CampanaG Janossy
Jun 1, 1994·Baillière's Clinical Haematology·W D LudwigE Thiel
Oct 1, 1983·British Journal of Haematology·M BaccaraniS Tura
Jan 1, 1985·Clinical and Laboratory Haematology·A M PereiraD Catovsky
Jan 1, 1987·Clinical and Laboratory Haematology·D BarnettG A Buckley
Aug 9, 2005·Annals of Diagnostic Pathology·Xin Han, Carlos E Bueso-Ramos
Jul 1, 1985·The Veterinary Clinics of North America. Small Animal Practice·C E Leifer, R E Matus

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.